Aerva lanata

Aerva lanata

1. Identity and Botanical Description

Full scientific name: Aerva lanata (L.) A. L. Juss. ex Schultes (family Amaranthaceae), locally known as 'bui', is an erect or prostrate undershrub with a long taproot and many woolly-tomentose branches, found in the wild throughout India. It can be found growing up to approximately 900 metres above sea level on mountain slopes.

Geographical distribution: Aerva lanata (L.) Juss. (Amaranthaceae) is an important medicinal plant growing as a common weed in fields and wasteland in tropical regions of Africa and Asia. It is widely spread in the drier parts of the tropics and subtropics of the world.

Common and vernacular names: The plant is called Mountain Knotgrass in English, Polpala in Sinhalese, Cherula/Cheroola in Malayalam, Gorakhbuti in Hindi, Bilesuli in Kannada, Chaya in Bengali, Pindi Kura in Telugu, Kapuri Madhura in Marathi, and Bhui in Rajasthan. It is commonly known as Mountain Knotgrass or Gorakhabooti in Hindi. In Ayurvedic literature it is referenced under names including Paashaanabheda, Gorakshaganjaa, Aadaanpaaki, and Shatkabhedi, as noted in the PMC review.

Morphological features: Aerva lanata is a common weed which grows wild everywhere in the plains of India. The root has a camphor-like aroma. The flowers are seen as clusters and are pale green in colour. The dried flowers, which look like soft spikes, are sold under commercial names such as Buikallan or Boor. The fruits and flowers are seen in the months of November to January.

Parts used and common forms: The entire plant is used medicinally, including its flowers, leaves, stems, and roots, in various forms such as juice and extracts. This herb is used as a decoction or as an herbal tea, with or without other herbs, in Ayurveda. In Sri Lanka, polpala tea is famous for cleansing the kidneys and is consumed regularly. The powder popularly called sirupeelai powder is also widely used in Tamil Nadu.

2. Traditional and Historical Use

Ayurveda (India)

Gorakshaganja–Aerva lanata is a plant mentioned in Ayurveda for the treatment of renal calculi, retention of urine, cough, and sore throat. In Ayurveda, A. lanata is described as a diuretic with anti-inflammatory, antibacterial, anthelmintic, and analgesic effects and as an agent used in the treatment of diabetes. Leaf and root paste has anti-inflammatory and antibacterial properties and is applied to treat pustules and skin infections.

Pashanabheda plants are a group of medicinal plants used in the Indian traditional medicinal system by Ayurveda practitioners as antiurolithiatic drugs, and A. lanata is used conventionally as both antiurolithiatic and diuretic. Aerva lanata is commonly described in Ayurveda as a diuretic with anti-inflammatory, antihelmintic, antibacterial, and mild analgesic effects, and it is used in the treatment of lithiasis, cough, asthma, and headache and as an antidote for rat poisoning.

Siddha Medicine (South India)

Urinary disorders are treated with Aerva lanata in the southern parts of India as a source of Pashana Beda (Stone Breaker). Most Ayurveda and Siddha practitioners in south India use this plant for urinary disorders such as Ashmari (urinary calculi), Moothra Krichra (dysuria), and Mootra Vikara. A decoction known as Sirupeelai Samoola Kudineer, prepared by combining four herbs including the whole plant of Aerva lanata, root of Crataeva nurvala, fruit of Tribulus terrestris, and root of Pavonia odorata, is used therapeutically to treat urolithiasis in the Siddha system of medicine practised in South India.

Tibb-e-Unani and Other Regional Traditions

While Aerva lanata has been less documented in certain traditional texts, it has appeared in historical medical practices, particularly in Tibb-e-Unani and Ayurvedic literature. Renowned practitioners have referenced the herb under various names, emphasising its cultural significance across different regions. Additionally, its historical usage in Sri Lanka for treating sore throats and coughs further extends its ethnobotanical importance.

African Traditional Medicine

Aerva lanata is a Nigerian medicinal plant used traditionally for the management of lithiasis, headache, renal disorder, haematemesis, bronchitis, nasal bleeding, cough, scorpion stings, fractures, and spermatorrhoea. In Nigeria, the Yoruba refer to it as Ewi-owo or Ewe Aje while the Hausa call it Furfurata. It has been reported to be used to treat kidney-related infections, fever, guinea worm infection, diabetes, bleeding from a cut, and eye disease. Extracts made of Aerva lanata are given to pregnant women as a tonic to relieve stomach pains and prevent miscarriage.

Its extract is used in several regions for jaundice, liver congestion, dyspepsia, typhoid, pneumonia, biliousness, and prolonged fevers.

Sri Lanka

Polpala (Aerva lanata) is a medicinal plant that is extensively used for the treatment of renal disease in Ayurvedic medicine in Sri Lanka. Polpala [Aerva lanata] is an important medicinal plant found throughout tropical India as a common weed in fields and wasteland. Even now, wild collection of the species continues to be a source of raw drug in Ayurvedic preparations. Because of its popularity in folk medicine, A. lanata has become the subject of intense pharmacological and chemical studies for the last 30 years.

3. Phytochemical Constituents

Alkaloids

The phytochemical constituents present in the plant include alkaloids: ervine, methylervine, ervoside, aervine, methylaervine, aervoside, ervolanine, and aervolanine. It contains a wide variety of phytochemicals, including flavonoids, phenolic acids, steroids, terpenoids, canthin-6-one and β-carboline alkaloids, which contribute to its broad spectrum of pharmacological actions.

Flavonoids

Flavonoids present include kaempferol, quercetin, isorhamnetin, persinol, and persinosides A and B. Some of the isolated compounds include kaempferol, tiliroside, β-sitosterol, aervoside, syringic acid, and canthin-6-one.

Terpenoids and Steroids

Additional constituents include methyl grevillate, lupeol, lupeol acetate, benzoic acid, β-sitosteryl acetate, and tannic acid. Sitosteryl palmitate, hentriacontane, β-sitosterol and its D-glucoside, α-amyrin, and betulin were also isolated from the plant. The methanolic extract of stem, leaves, root, flower, and seeds of A. lanata showed the presence of 30 different types of steroids with 30 different Rf values from 0.04 to 0.97, with the maximum number (11) of steroids observed in leaves, followed by root (10).

Phenolic Acids

A study investigated the chemical composition of phenolic acid (PA)-rich fractions isolated from methanolic extracts of A. lanata herb. The free PA fraction (FA), the PA fraction (FB) released after acid hydrolysis, and the PA fraction (FC) obtained after alkaline hydrolysis were analysed using LC-ESI-MS/MS. The phenolic profile of each sample showed a high concentration of PAs and their presence in A. lanata herb mainly in bound states. Thirteen compounds were detected and quantified in all samples, including some PAs that had not been previously detected in this plant species.

Other Compounds

Organic extracts such as ethanol, ethyl acetate, chloroform, acetone, water, and methanol have been subjected to various phytochemical analyses and confirmed for the existence of flavonoids, glycosides, terpenoids, and alkaloid-containing components. Preliminary phytochemical study revealed the presence of alkaloids, saponins, anthraquinone, tannins, phenolics, flavonoids, glycosides, terpenoids, amino acids, steroids, protein, coumarin, and quinone.

4. Pharmacology and Mechanisms of Action

Antiurolithiatic (Anti-Kidney Stone) Activity

Among the various extracts, the aqueous extract of this plant was shown to be potent in dissolving kidney stones in many studies. The plant has been reported to contain quercetin and betulin, which have antiurolithiatic action associated with diuretic activity.

In a study screening compounds isolated from A. lanata for antiurolithiatic potential, an ethylene glycol (0.75% v/v)-induced urolithiasis model was used in male Wistar albino rats. The animals were divided into five groups containing six each. Based on the LD50 of the plant extract (2000 mg/kg b.w.), equivalent doses were calculated. Two isolated compounds (quercetin and betulin) were screened for antiurolithiatic potentials by administering 2 mg/kg b.w./day orally as the test dose for 28 days.

The urine volume was significantly increased from 12.76 ± 0.10 ml to 21.35 ± 0.20 ml in rats treated with quercetin and 21.50 ± 0.21 ml in rats treated with betulin. Urine microscopy revealed significant reduction (p < 0.001) in the size of calculi and significantly enhanced (p < 0.001) excretion of calcium, oxalate, and phosphate, whereas the level of magnesium was increased. SEM of kidney sections revealed reduction in calculi in treated animals. Serum analysis revealed significant reduction in the level of BUN and creatinine. The isolated quercetin and betulin from A. lanata showed mild diuretic effect as well as antiurolithiatic effect by significantly reducing the size of calculi in the kidneys and enhancing the excretion of calcium, phosphate, and oxalate while maintaining the level of magnesium, which is reported to be one of the calculi inhibiting factors.

Evidence level: This is preclinical, animal-based evidence only. Further research is needed to explore the full therapeutic potential of Aerva lanata to establish it as a reliable standard drug due to its promising preclinical results. No robust human clinical trials on the antiurolithiatic effect of Aerva lanata alone were identified in the peer-reviewed literature searched.

Diuretic Activity

A study comparing the diuretic activity of concentrated ethanolic extract of Aerva lanata and Aerva tomentosa on healthy albino rats showed increased urine output with ethanolic extract of Aerva lanata only. The control drug used was frusemide, but the diuretic activity was slightly less compared to frusemide.

One human-relevant observation was documented in Sri Lankan research: when given to humans in concentrations of 50 g/200 ml and 100 g/200 ml, a significant increase in urine volume was observed when compared with controls in one study in which the diuretic property was determined by measuring urine output. Crude aqueous plant extract showed diuretic activity with marked increase in urine output, urine osmolality, and urinary potassium excretion. The low molecular mass fraction of dried plant material showed a significant diuretic effect while the high molecular fraction did not have the same effect.

Evidence level: Diuretic activity has been demonstrated in animal models and in one small human observation study in Sri Lanka. This represents preliminary, low-certainty human evidence; formal randomised controlled trials have not been identified.

Anti-inflammatory Activity

The antioxidant (DPPH• and ABTS•+) and anti-inflammatory (xanthine oxidase, lipoxygenase) activities of the crude methanol extract and dry phenolic acid fractions obtained from Aerva lanata were determined. Among the fractions, the highest antioxidant capacities in the DPPH• and ABTS•+ assay were detected for fraction B: 2.85 mM Trolox/g dry weight of fraction and 2.86 mM Trolox/g dry weight of fraction, respectively.

In an in-vitro study, acetone extract of A. lanata showed considerable antidiabetic (α-amylase: 71.7% and α-glucosidase: 70.1%) and moderate anti-inflammatory (59% and 49.8%) activities.

Evidence level: Anti-inflammatory effects are supported by in-vitro (enzyme inhibition and cell-based) and animal models only. No human clinical evidence specific to anti-inflammatory outcomes was identified.

Antidiabetic / Hypoglycaemic Activity

Alpha glucosidase inhibition, antiglycation, and adipogenic potential significantly contribute to the antidiabetic property of Aerva lanata. In addition, insulin sensitisation and antioxidant potential also enhance its therapeutic potential.

The Partially Purified Alkaloid Basified Toluene Fraction (PPABTF) of the roots of Aerva lanata showed antihyperglycaemic activity against type 2 diabetes induced by streptozotocin-nicotinamide in rats. Dose-dependent oral administration of ethanolic extract of Aerva lanata improved blood glucose level, which was comparable to the standard drug metformin in four weeks of treatment in alloxan-induced diabetic rats.

Though there are reports on the hypoglycaemic and antidiabetic potentials of Aerva lanata, detailed information on the inhibition of α-amylase and α-glucosidase by the plant has been more recently studied. This study presents inhibitory effects of the Aerva lanata extract on diabetes-related enzymes and free radical-scavenging properties of the plant. It can be suggested that the antidiabetic activities of the Aerva lanata extracts may be due to the phenolic composition of the plant and its antioxidant properties.

Results from a 2021 study clearly indicate a potent α-glucosidase inhibitory effect of the phenolic acid fractions isolated from the herb of A. lanata.

Evidence level: All antidiabetic evidence is from in-vitro enzyme inhibition assays and animal models (streptozotocin- and alloxan-induced diabetes). No human clinical trials on antidiabetic effects of Aerva lanata were identified.

Hepatoprotective Activity

Previous research on A. lanata showed that different parts of this plant have anti-cancer, anti-diabetic, anti-inflammatory, nephroprotective, hepatoprotective, and antihelminthic properties. A study evaluated the protective effect of ethanol extract of Aerva lanata (EEAL) in preventing acetaminophen-induced liver toxicity both in isolated primary hepatocytes in vitro and in Sprague-Dawley rats in vivo. Expression of GST, Nrf2, COX1, and COX2 genes in rat liver were evaluated by RT-PCR. The results showed that acetaminophen induced down-regulation of Nrf2 and upregulation of GST gene expression, which were modulated by EEAL treatment.

Animals treated with doses of 100, 200, and 300 mg/kg of plant extracts showed significant protection of the liver histologically and in serum tests after the last doses of CCl4. Thus the study reveals that plant extracts from A. lanata have significant hepatoprotective property.

Evidence level: Hepatoprotective effects have been documented in rodent models using various hepatotoxic agents (acetaminophen, carbon tetrachloride, paracetamol). All evidence is preclinical; no human clinical data were identified.

Nephroprotective Activity

The ethanol extract of the entire plant of Aerva lanata was studied for its nephroprotective activity in cisplatin- and gentamicin-induced acute renal injury in albino rats. In the curative regimen, the extract at dose levels of 75, 150, and 300 mg/kg showed dose-dependent reduction in elevated blood urea and serum creatinine and normalised histopathological changes. In the gentamicin model, the rats in the preventive regimen also showed good response to the ethanol extract at 300 mg/kg. The findings suggest that the ethanol extract of Aerva lanata possesses marked nephroprotective activity with minimal toxicity and could offer a promising role in the treatment of acute renal injury caused by nephrotoxins like cisplatin and gentamicin.

The methanol extract showed excellent nephroprotective activity (97.04%) at 20 μg/mL concentration on cisplatin (8 μg/mL)-exposed HEK 293 cell line and it was almost comparable with the standard nephroprotective drug quercetin.

Evidence level: Nephroprotective evidence is based on animal and cell-line studies only. No human randomised trials were identified.

Antiasthmatic and Immunomodulatory Activity

Aerva lanata is traditionally used for cough, sore throat, and asthma. A study investigated the immunomodulatory and anti-inflammatory potentials of A. lanata in allergic asthmatic mice. BALB/c mice were administered three different extracts (methanol, n-hexane, and ethyl acetate) of A. lanata two weeks after immunisation with ovalbumin and continued for 7 days. Inflammatory cells count was estimated in blood and broncho-alveolar lavage fluid (BALF). RT-PCR was used to measure mRNA expression levels of inflammatory mediators. GC-MS analysis was also carried out. Among three extracts of A. lanata, the ethyl acetate extract significantly ameliorated (p < 0.001) count of inflammatory cells in both blood and BALF. This study indicated that ethyl acetate extract of A. lanata lowered (p < 0.001) the level of inflammatory modulator TNF-α and IgE antibodies.

The anti-asthmatic effect of A. lanata might be contributed by the suppression of oedema, pro-inflammatory cytokines, and IgE antibodies, and elevation of aquaporin expression levels, suggesting future study and clinical trials to propose it as a candidate to treat allergic asthma. The antioxidant phytochemicals present in A. lanata might be responsible for such potential.

Aerva lanata is an important medicinal plant widely used in traditional systems of medicine like Ayurveda and Siddha. Ethanolic extract of the whole plant of A. lanata exhibited immunomodulatory and antitumour activity. Intraperitoneal administration of five doses of the extract (10 mg/kg body weight) was found to enhance the total WBC count (14,238 cells/mm³), bone marrow cellularity (22.33 × 10⁶ cells/femur), and number of α-esterase-positive cells (1276 cells/4000 cells). Aerva treatment also showed enhanced proliferation of splenocytes, thymocytes, and bone marrow cells both in the presence and absence of specific mitogens in vitro and in vivo.

Evidence level: Antiasthmatic and immunomodulatory effects are supported by animal models (ovalbumin-induced asthma in mice) and in-vitro studies. No human clinical trials were identified.

Antimicrobial Activity

A study aimed to determine the phytochemical components, microbial inhibitory effectiveness, and antioxidant properties of Aerva lanata plant extracts. The whole plant showed various medicinal applications in folklore and traditional medicine in various parts of the world. Organic extracts such as ethanol, ethyl acetate, chloroform, acetone, water, and methanol were subjected to various phytochemical analyses and confirmed for the existence of flavonoids, glycosides, terpenoids, and alkaloid-containing components. The extracts were also tested for antibacterial activities against microbial pathogens and antioxidant properties. Results indicated that the solvent extracts showed prominent activity against the tested strains, and the MIC concentrations of plant were detected from 5 mg/mL to 40 mg/mL.

In another in-vitro study, acetone extract showed considerable antimicrobial activity against bacteria in the order S. aureus > E. coli > K. pneumoniae > P. aeruginosa > B. subtilis, and for fungi T. viride > A. flavus > C. albicans > A. niger, at 30 mg/mL concentration.

Evidence level: Antimicrobial evidence is exclusively in-vitro. Clinical application has not been validated in human trials.

Antitumour and Cytotoxic Activity

Petroleum ether extract of Aerva lanata showed significant cytotoxicity against Dalton's lymphoma ascites (DLA) tumour cell lines in vitro and stimulated lymphocyte proliferation in both in vitro and in vivo conditions. DLA-bearing animals treated with A. lanata showed increase in lifespan compared to control animals. The partially purified fraction was also found to be hepatoprotective, as evidenced from the normal levels of liver marker enzymes. The partially TLC-purified fraction of the petroleum ether extract proved to be cytotoxic to DLA, Ehrlich ascites (EA), and B16F10 cell lines in vitro. Since the partially TLC-purified fraction was found to be more cytotoxic to DLA cell lines, it was used to study the pharmacological effect and its potential to reduce solid tumour induced by DLA cell lines in mice.

Preliminary phytochemical analysis of the partially purified fraction showed the presence of alkaloids. These results indicate that the fraction contains non-toxic immunomodulatory compounds.

Evidence level: Antitumour effects are demonstrated only in cell line and murine models. No human oncology trials have been reported.

Antifertility Activity

The aerial portion of Aerva lanata was extracted with ethanol and appraised for its antifertility attributes employing anti-implantation, aborticide, and spermatozoa motility of rat (in vitro) models. The anti-implantation effect appeared to be dose-dependent, as well as related to the time of treatment initiation during pregnancy; pre-implantation loss was observed. At a concentration of 10%, Aerva lanata exhibited no motility of spermatozoa (rats) within 60 seconds.

Histologically, the treated pup testes tissues showed varying degrees of disruption and distortion of the cellular arrangements of the germinal epithelium in a dose-dependent manner compared to the control. The study revealed a testicular toxicity and possibly antifertility role of Aerva lanata in dams' pups.

Evidence level: Antifertility and reproductive toxicity evidence is animal-based. This has significant safety implications (see Section 7).

Hypolipidaemic Activity

Pharmacological studies have reported hypolipidemic properties of Aerva lanata. In animal models, A. lanata has been evaluated for hypolipidaemic effects in the context of ethylene glycol-induced urolithiasis in rats, with studies (referenced in source literature) reporting changes in lipid profiles in treated animals, though these findings are preliminary and animal-only.

Anthelmintic (Anti-parasitic) Activity

Methanol and aqueous extracts of Aerva lanata Linn. Juss. were taken for anthelmintic activity against the Indian earthworm Pheretima postuma. Various concentrations of both extracts were tested and results were expressed in terms of time for paralysis and time taken for death of worms. Piperazine citrate (10 mg/mL) was used as reference standard and normal saline as a control group. Dose-dependent activity was observed in both extracts, and the methanol extract possessed more activity than the aqueous extract.

Evidence level: Anthelmintic effects are in-vitro only; no clinical trial data were identified.

5. Body Systems and Health Areas

• Urinary / Renal System: Antiurolithiatic (kidney stone reduction), diuretic, nephroprotective against nephrotoxin-induced injury, dysuria relief.
• Hepatic (Liver) System: Hepatoprotective against acetaminophen- and carbon tetrachloride-induced hepatotoxicity; normalisation of liver enzyme markers.
• Metabolic / Endocrine System: Antidiabetic and hypoglycaemic activity via α-amylase and α-glucosidase inhibition, antiglycation, and insulin sensitisation.
• Respiratory System: Traditional use for cough, asthma, and sore throat; experimental suppression of pro-inflammatory cytokines (TNF-α) and IgE in allergic asthma models.
• Immune System: Immunomodulatory effects; stimulation of lymphocyte, splenocyte, and bone marrow cell proliferation in animal models.
• Integumentary System: Traditional topical application of leaf/root paste for pustules and skin infections.
• Gastrointestinal System: Traditional use for dyspepsia and antidiarrhoeal activity reported in animal models.
• Cardiovascular / Lipid Metabolism: Hypolipidaemic properties reported in animal models.
• Reproductive System: Antifertility and anti-implantation activity in animal studies (also a safety concern — see Section 7).

Numerous studies have confirmed its versatile pharmacological activities: anthelmintic, demulcent, anti-inflammatory, diuretic, expectorant, hepatoprotective, nephroprotective, anti-diabetic, anti-hyperglycaemic, anti-microbial, cytotoxic, antiurolithiatic, hypoglycaemic, anti-hyperlipidaemic, anti-parasitic, and antihelmintic activities.

6. Dosage Forms and Reported Study Dosages

The following dosages appear specifically in the peer-reviewed source literature and are reported as used in experimental studies, not as recommended human doses.

• Antiurolithiatic (animal study): Two isolated compounds (quercetin and betulin) of A. lanata were screened for antiurolithiatic potentials in calculi-induced male Wistar albino rats by administering 2 mg/kg b.w./day orally as test dose for 28 days.
• Nephroprotective (animal study): The extract at dose levels of 75, 150, and 300 mg/kg showed dose-dependent nephroprotective reduction in elevated blood urea and serum creatinine in rats treated with cisplatin. In the gentamicin model, the preventive regimen also showed good response at 300 mg/kg.
• Hepatoprotective (animal study, carbon tetrachloride model): Extracts were administered at the dose of 50 and 100 mg/kg body weight for 14 days in a carbon tetrachloride–hepatotoxicity model in rats.
• Hepatoprotective (animal study, acetaminophen model): For in vivo studies, animals were grouped as: Group I – Control; Group II – acetaminophen (2 g/kg b.w.); Group III – EEAL (50 mg/kg b.w.) + acetaminophen (2 g/kg b.w.); Group IV – EEAL (100 mg/kg b.w.) + acetaminophen (2 g/kg b.w.).
• Immunomodulatory (animal study): Intraperitoneal administration of five doses of the extract at 10 mg/kg body weight was used to evaluate immunomodulatory effects.
• Diuretic (human observation): Concentrations of 50 g/200 ml and 100 g/200 ml were given to humans in one study where a significant increase in urine volume was observed compared to controls.
• Antiurolithiatic (animal study, aqueous extract, curative regimen): Rats in the curative regimen groups received extract at 500 and 1000 mg/kg body weight from day 15 till day 28, once daily by oral route.
• Long-term renal toxicology (animal study): Thirty male and thirty female healthy rats were administered dried infusion of A. lanata at 25 g/200 mL (low dose) or 100 g/200 mL (high dose) and distilled water (control) for 30 days.
• Antifertility (animal study): 25 pregnant Wistar rats were randomly divided into 5 groups. Groups B, C, D, and E received 200, 400, 800, and 1000 mg/kg body weight of Aerva lanata extract, respectively, beginning from the 12th day of gestation.

7. Safety Considerations and Documented Concerns

Acute and Sub-Chronic Toxicity

Acute toxicity tests for the aqueous extract administered orally at 1–30 g/kg and intraperitoneally at 0.1–2 g/kg were carried out in albino mice; a sub-chronic toxicity test was done by daily oral administration at 40–1000 mg/kg to albino rats for 90 days. Anthropometric, biochemical, and haematological parameters and vital organs histological examinations were performed.

The overall findings suggest that the aqueous extract of A. lanata is relatively safe on acute oral exposure, moderately toxic on acute intraperitoneal administration, and is relatively safe with antioxidant actions on prolonged exposure. However, it shows potentials for toxic effects such as cellular damage to organs, dyslipidaemia, and reduction in male reproductive capacity. Caution must therefore be applied in its use on a long-term basis.

Renal Structural Effects with Long-Term Use

Aerva lanata is not prescribed for long-term use in Ayurveda, as it is believed to produce structural changes in the urinary tract of patients, leading to renal failure. This traditional caution is partially supported by experimental evidence: administration of dried Aerva lanata for a period of one month did not produce significant effects on renal function of rats, however administration for the same period caused significant ultrastructural changes in the proximal convoluted tubular epithelial cells.

It is believed that long-term ingestion of Aerva lanata is harmful, as it has adverse effects on the urinary tract.

Reproductive Toxicity and Antifertility Concern

In addition to other characterised properties, Aerva lanata possesses antifertility and anti-implantation activities. Histologically, the treated pup testes tissues showed varying degrees of disruption and distortion of the cellular arrangements of the germinal epithelium in a dose-dependent manner compared to the control; the study revealed testicular toxicity and a possibly antifertility role of Aerva lanata in dams' pups. These findings are from animal studies, but they raise concern for use during pregnancy and in individuals of reproductive age.

Drug Interactions (Preclinical Signal)

People who are on diabetic medication should be careful while consuming Aerva lanata, as taking both diabetic medication and the herb might lower blood sugar levels drastically. This pharmacodynamic interaction signal is based on the plant's demonstrated α-glucosidase and α-amylase inhibitory effects.

LD50 and General Toxicity Reference

The LD50 of the plant extract was established at 2000 mg/kg b.w. in one antiurolithiatic study. The aqueous extract of Aerva lanata was reported to be safe orally and exhibited no gross behavioural changes in rats at the doses evaluated in a urolithiatic animal model.

Overall Evidence Gaps

It is widely used, but there are very few scientific data about its chemical composition and pharmacological activity relative to its breadth of traditional use. While traditional use and preclinical studies support its therapeutic role, further clinical trials are necessary to validate its efficacy, safety, and appropriate dosage in humans. The vast majority of positive pharmacological findings for Aerva lanata remain at the level of in-vitro cell assays and rodent models, and no large-scale, well-controlled human clinical trials for any therapeutic indication were identified in the peer-reviewed literature searched.

References

• Goyal M, et al. "Aerva lanata: A review on phytochemistry and pharmacological aspects." Pharmacognosy Reviews, 2012. PMC3263055.
• Goyal M, et al. "Aerva lanata: A review on phytochemistry and pharmacological aspects." PubMed PMID 22279378.
• Paplińska-Goryca M, et al. "Antioxidant, Anti-Inflammatory, and Anti-Diabetic Activity of Phenolic Acids Fractions Obtained from Aerva lanata (L.) Juss." Molecules, 2021;26(12):3486.
• Paplińska-Goryca M, et al. (PMC version) "Antioxidant, Anti-Inflammatory, and Anti-Diabetic Activity of Phenolic Acids Fractions Obtained from Aerva lanata (L.) Juss." PMC8228310.
• Paplińska-Goryca M, et al. PubMed PMID 34201147.
• Behera PC, Ghosh M. "Antiurolithiatic activity of natural constituents isolated from Aerva lanata." PMC5747499.
• Behera PC, Ghosh M. PubMed PMID 29169771.
• Behera PC, Ghosh M. "Antiurolithiatic activity of natural constituents isolated from Aerva lanata." ScienceDirect, Ancient Science of Life, 2016.
• Akanji MA, Olukolu SO, Kazeem MI. "Leaf Extracts of Aerva lanata Inhibit the Activities of Type 2 Diabetes-Related Enzymes and Possess Antioxidant Properties." Oxidative Medicine and Cellular Longevity, 2018. PMC6178189.
• Antidiabetic property of Aerva lanata (L.) Juss. ex Schult. is mediated by inhibition of alpha glucosidase, protein glycation and stimulation of adipogenesis. PubMed PMID 25224159.
• Mechanism of protection of rat hepatocytes from acetaminophen-induced cellular damage by ethanol extract of Aerva lanata. PMC7247370.
• Gunatilake M, Lokuhetty D. "Aerva lanata (Polpala): Its effects on the structure and function of the urinary tract." PMC3510869.
• Gunatilake M, Lokuhetty D. PubMed PMID 23225960.
• Siveen KS, Kuttan G. "Immunomodulatory and antitumor activity of Aerva lanata ethanolic extract." PubMed PMID 20979430.
• Nevin KG, Vijayammal PL. "Pharmacological and Immunomodulatory Effects of Aerva lanata in Daltons Lymphoma Ascites-Bearing Mice." Pharmaceutical Biology, 2005.
• Sharif M, Anjum I, Shabbir A, Mushtaq MN. "Immunomodulatory and anti-inflammatory effects of Aerva lanata in ovalbumin induced allergic asthmatic mice." Journal of Ethnopharmacology, 2022. PMID 35143934.
• Sharif M, et al. "Immunomodulatory and anti-inflammatory effects of Aerva lanata in ovalbumin induced allergic asthmatic mice." ScienceDirect, 2022.
• Suresh Mickymaray, et al. "Identification of phytochemical components from Aerva lanata (Linn.) medicinal plants and its in-vitro inhibitory activity against drug resistant microbial pathogens and antioxidant properties." PMC6734131.
• Suresh Mickymaray, et al. PubMed PMID 31516340.
• Omotoso KS, et al. "Toxicological evaluation of the aqueous whole plant extract of Aerva lanata (l.) Juss. ex Schult (Amaranthaceae)." Journal of Ethnopharmacology, 2017. ScienceDirect.
• Anti-fertility effect of Aerva lanata crude extract in male Dams offspring: An experimental study. PMC10133732.
• Antiurolithiatic Effect of Sirupeelai Samoola Kudineer: A Polyherbal Siddha Decoction on Ethylene Glycol-induced Renal Calculus in Experimental Rats. PMC5538166.
• Chromatographic finger print analysis of steroids in Aerva lanata L by HPTLC technique. PMC3614217.
• Rajesh R, et al. "Aerva lanata (Linn.) Juss. ex Schult. – An overview." Indian Journal of Natural Products and Resources, 2011.
• A Review on Aerva lanata: Avenue of Medicinal Properties. Journal of Population Therapeutics and Clinical Pharmacology, 2023.
• Review of Aerva lanata: Traditional uses and pharmacological actions. World Journal of Pharmaceutical Research.
• Pharmacological Properties of the Plant Aerva lanata – A Review. Journal of Clinical and Diagnostic Research, 2023.
• Assessment of antimicrobial, antidiabetic, and anti-inflammatory properties of acetone extract of Aerva lanata (L.) by in-vitro approach and bioactive compounds characterization. PubMed PMID 38295976.